Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg hikes target price on Coats following H1 numbers

(Sharecast News) - Analysts at Berenberg raised their target price on thread and structural components manufacturer Coats Group from 100.0p to 120.0p on Friday as it said the group was "knitting it all together" during H1. Berenberg said Coats' interim results for the six months to 30 June showed "a highly credible organic growth performance" and noted that a slight upgrade to FY24 guidance, stronger-than-expected margin performance and incrementally more positive commentary about the market recovery saw the shares react strongly on the day after having been range-bound for the past few years.

"At a current valuation of 12.5x FY25 P/E, we still see a lot to like in the shares. We move our price target to 120p (from 100p) as the group enters into what we expect could be the start of a sustained market recovery and upgrade cycle," said Berenberg, which stood by its 'buy' recommendation on the stock.

"We roll our previous valuation methodology of 15x FY1 P/E over from our FY24 forecasts to our FY25 forecasts. Beyond mechanics, we also think it is logical to assign more value to Coats on the back of its H1 results: organic growth has continued to build, with all three divisions in growth in Q2, and this is expected to continue; margins of 18% were provably ahead of management's FY24 target; and volumes and destocking trends have continued to normalise into what now looks like a sustainable market recovery."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

Berenberg lowers target price on Impax Asset Management
(Sharecast News) - Analysts at Berenberg lowered their target price on Impax Asset Management from 620.0p to 560.0p on Tuesday but noted that outflows had started to slow.
GSK's Arexvy provides protection over three RSV seasons, trial shows
(Sharecast News) - GSK has announced positive results from a phase III trial of its Arexvy RSV vaccine, showing that just one dose of the treatment could help protect older adults at risk of RSV disease over three seasons.
S&U revenue up, profitability a challenge in first half
(Sharecast News) - Motor and property finance specialist S&U reported a mixed first-half financial performance on Tuesday, after group revenue increased 9% year-on-year to £60.4m.
Loungers reports slight slowdown in LFL sales growth
(Sharecast News) - Cosy Club owner Loungers reported a slight slowdown in like-for-like sales growth on Tuesday and a jump in revenue.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.